Background Millions of people worldwide suffer from hepatitis C, which can lead to severe
liver disease, liver cancer, and death. Direct‐acting antivirals (DAAs), eg sofosbuvir, are …

Background Direct‐acting anti‐virals (DAAs) licensed to treat chronic HCV infection have
revolutionised treatment algorithms by drastically mitigating side effects while enhancing …

Introduction: Currently, direct-acting antivirals (DAAs) are considered the ideal choice for the
treatment of chronic HCV patients due to their proven efficacy (SVR> 90%), and minimal …

Hepatitis C virus (HCV) alters mitochondrial dynamics associated with persistent viral
infection and suppression of innate immunity. Mitochondrial dysfunction is also a pathologic …

Australia's recent investment in, and optimism about, direct-acting antivirals to treat hepatitis
C brings with it the promise of new drug futures, including the possibility of a post-hepatitis C …

The occurrence of hepatocellular carcinoma (HCC) is one of the most serious complications
of hepatitis C virus (HCV) infection. Recently, effective antiviral medications have made …

Background: In a prospective, single-center open study, we evaluated the very long-term
effects of rituximab (RTX) administered to patients with severe mixed cryoglobulinemia (MC) …

Abstract Background and Aim: Radiofrequency ablation (RFA) is an established treatment
for small hepatocellular carcinoma (HCC) wherein non‐recurrence is essential for long‐term …

Aims: To systematically evaluate the literature for evidence to support the use of bile acids in
non-cholestatic liver conditions. Methods: Searches were conducted on the databases of …

Introduction: Hepatitis C virus is a hepatotropic virus that generally leads to chronic hepatitis
and various harmful sequelae. The lone standard of treatment has been pegylated interferon …